Premium
Tamoxifen‐inducible podocyte‐specific iCre recombinase transgenic mouse provides a simple approach for modulation of podocytes in vivo
Author(s) -
Wang Jinrong,
Wang Yin,
Long Jianyin,
Chang Benny H.J.,
Wilson Mathew H.,
Overbeek Paul,
Danesh Farhad R.
Publication year - 2010
Publication title -
genesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.093
H-Index - 110
eISSN - 1526-968X
pISSN - 1526-954X
DOI - 10.1002/dvg.20635
Subject(s) - podocin , tamoxifen , cre recombinase , recombinase , transgene , genetically modified mouse , biology , reporter gene , in vivo , microbiology and biotechnology , podocyte , gene , kidney , endocrinology , recombination , genetics , gene expression , cancer , breast cancer , proteinuria
We report the generation and initial characterization of a mouse line expressing tamoxifen‐inducible improved Cre (iCre) recombinase (iCre‐ER T2 ) under the regulation of NPHS2 (podocin) gene promoter. The resulting transgenic mouse line was named podocin‐iCreER T2 mice. The efficiency of iCre activity was confirmed by crossing podocin‐iCreER T2 with the ROSA26 reporter mouse. By using the floxed ROSA reporter mice, we found that tamoxifen specifically induced recombination in the kidneys. In the absence of tamoxifen, recombination was undetectable in podocin‐iCreER T2 ;ROSA26 mice. However, following intraperitoneal injection of tamoxifen, selective recombination was observed in the podocytes of adult animals. We further examined the efficiency of recombination by assessing various tamoxifen exposure regimens in adult mice. These results suggest that podocin‐iCre‐ER T2 mouse provides an excellent genetic tool to examine the function of candidate genes in podocytes in a spatially and temporally‐restricted manner. genesis 48:446–451, 2010. © 2010 Wiley‐Liss, Inc.